Evaluation of Dentin Hypersensitivity Using Glass Ionomer Cements

Federal University of Pelotas20 enrolled

Overview

The aim of this randomized, double-blind, split-mouth clinical trial is to evaluate and compare the desensitizing efficacies of the resin-modified glass ionomer cement ClinproTM XT (3M ESPE, Minnesota, USA) and the conventional glass ionomer cement Vidrion R (SS White, Gloucester, UK) at 2-year follow-up.

Subjects will require to have at least two teeth in different hemiarchs with dentin hypersensitivity. Teeth will be randomized into 2 groups, receiving either Clinpro XT or the conventional glass ionomer cement Vidrion R. Prior to the desensitizing treatment (baseline), painful symptoms will be assessed by tactile and air blast tests using the Visual Analogue Scale (VAS). Treatment evaluations will be conducted up to 2-year post-treatment.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

DOUBLE

Enrollment

Conditions

Dentin Hypersensitivity

Interventions

Resin-modified glass ionomer cement Clinpro XTDRUG

Clinpro XT (3M ESPE, Minnesota, USA)

Glass Ionomer cement Vidrion RDRUG

Vidrion R (SS White, Gloucester, UK)

Eligibility

Sex: ALLMin age: 28 YearsMax age: 70 YearsHealthy volunteers:

Medical Language ↔ Plain English

Inclusion Criteria: * Male and female subjects between 18 and 70 years old * At least 2 teeth with dentin hypersensitivity in two different hemiarchs * Dental elements with hypersensitivity without any pulp alteration * People who are not taking any medication and women who are not pregnant * Patients without eating disorders or very acidic diets. Exclusion Criteria: * Teeth with hypersensitivity that presented extensive or unsatisfactory restorations, fractures, periodontal alterations, caries lesions, orthodontic brackets, endodontic treatments, pulp alterations. * Subjects who received any desensitizing therapy during the last 3 months * Subjects being under analgesics/anti-inflammatory drugs at the time of the study * Teeth with hypersensitivity and non-carious cervical lesions

Outcomes

Primary Outcomes

Pain Scores as measured by the Visual Analog Scale (VAS)

Tactile and air blast tests to evaluate pain with VAS

Time frame: Change from Baseline in Pain Scores at 20 minutes; at 7, 15, 21, 30 days; and after 3, 6, 12, 24 months.

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.